Nutrinia is developing drug products to treat acute to chronic intestinal failure based on its proprietary Oral Insulin technology. These drug products will treat rare diseases of the gastrointestinal tract and impact short- and long-term morbidities of pre-term infants, children, and adults.
Treating with insulin is not that simple. Human insulin is composed of 51 amino acids, proteins with a limited shelf life and relatively high sensitivity to environmental conditions such as high temperature, humidity and oxidative stress.
Adding to the difficulty is the fact that drug formulation for use in NICU for infant consumption has very stringent requirements. Infants require feeding via the thinnest feeding tube, exacting drug uniformity for very tiny amounts and approved excipients for consumption.
Nutrinia’s technology overcame the challenge of manufacturing insulin for oral administration.
Nutrinia’s insulin formulation is a powder for reconstitution. It is composed of insulin with excipients already approved for infant consumption, making it a safe drug product for infants. The formulation is shown to target and treat local GI with no absorption and with no systemic exposure. It has been shown to increase enteral nutrition absorption, which improves development and associated long-term outcomes. At the same time, it has been proven to reduce parenteral nutrition consumption in the short term, in multiple pre-clinical and clinical studies.
New Generation Technologies
100,000 Animals In Glp And Non Glp Studies
9 Preterms At Intestinal Failure Dose
15,000 Administrations In Human Trials